armanc/pubmed-rct20k · Datasets at Hugging Face

abstract_id stringlengths 8 8	label stringclasses 5 values	text stringlengths 1 1.39k	sentence_id int64 0 30
24672940	methods	The treatment period for the two groups was @ weeks .	3
24672940	methods	Patients were followed-up till the @th week .	4
24672940	methods	Clinical symptoms such as fever , lymphadenopathy and hepatosplenomegaly , as well as lab indices such as abnormal lymphocyte percentage , EB virus antibody , virus DNA load , T cell subsets , immunoglobulin , and so on were observed before and after treatment , at week @ and @ of follow-ups .	5
24672940	results	( @ ) The total effective rate at week @ was @ % in the treatment group , higher than that of the control group ( @ % ) , but there was no statistical difference between the two groups .	6
24672940	results	( @ ) The time for defervescence , duration of pharyngeal hyperemia , duration of swollen tonsils was shorter in the treatment group than in the control group ( P < @ ) .	7
24672940	results	The subsidence of lymphadenopathy , hepatomegaly , and abnormal lymphocytes was better in the treatment group than in the control group ( P < @ ) .	8
24672940	results	( @ ) The positive cases of peripheral blood hetero-lymphocyte was significantly reduced after treatment , at week @ and @ of follow-ups both in the treatment group and the control group ( P < @ ) .	9
24672940	results	The expression of IgA and IgM decreased after treatment in the two groups when compared with before treatment in the same group ( P < @ , P < @ ) .	10
24672940	results	IgG in the treatment group also obviously decreased after treatment , at week @ and @ of follow-ups ( P < @ , P < @ ) , while it decreased only after treatment in the control group ( P < @ ) .	11
24672940	results	Activities of AST and ALT in the treatment group and the AST activity in the control group were markedly improved when compared with those before treatment ( P < @ ) .	12
24672940	results	Compared with the control group , the abnormal lymphocyte positive case number obviously decreased in the treatment group after treatment , at week @ and @ of follow-ups ( P < @ ) .	13
24672940	results	( @ ) After treatment , at week @ and @ of follow-ups , CD@ + and CD@ + significantly decreased ; CD@ + , CD@/CD@ , and B cells significantly increased in the two groups , when compared with before treatment ( P < @ ) .	14
24672940	results	NK cells significantly increased more in the treatment group after treatment , at week @ and @ of follow-ups , higher than before treatment as well as the control group ( P < @ ) .	15
24672940	results	( @ ) EB viral DNA and EB viral CA-IgM negative conversion case numbers significantly increased in the two groups after treatment , at week @ and @ of follow-ups ( P < @ ) .	16
24672940	results	Compared with the control group , EB viral DNA and EB viral CA-IgM negative conversion case numbers significantly increased in the treatment group after treatment and at week @ of follow-ups ( P < @ ) .	17
24672940	conclusions	Treatment of EB virus infection by Chinese medical treatment was effective .	18
24672940	conclusions	It could promote the recovery of EB viral infection , and reduce the risk of vicious disease after EB viral infection .	19
25039547	objective	The primary objective was to compare the cosmetic outcomes of traumatic trunk and extremity lacerations repaired using absorbable versus nonabsorbable sutures .	0
25039547	objective	The secondary objective was to compare complication rates between the two groups .	1
25039547	methods	This was a randomized controlled trial comparing wounds repaired with Vicryl Rapide and Prolene sutures .	2
25039547	methods	Pediatric and adult patients with lacerations were enrolled in the study .	3
25039547	methods	At a @-day follow-up , the wounds were evaluated for infection and dehiscence .	4
25039547	methods	After @ months , patients returned to have the wounds photographed .	5
25039547	methods	Two plastic surgeons blinded to the method of closure rated the cosmetic outcome of each wound using a @-mm visual analog scale ( VAS ) .	6
25039547	methods	Using a noninferiority design , a VAS score of @ mm or greater was considered to be a clinically significant difference .	7
25039547	methods	We used a Student 's t-test to compare differences between mean VAS scores and odds ratios ( ORs ) to compare differences in complication rates between the two groups .	8
25039547	results	Of the @ patients enrolled , @ completed the study including @ in the Vicryl Rapide group and @ in the Prolene group .	9
25039547	results	The mean ( SD ) age of patients who completed the study was @ ( @ ) years , and @ were male .	10
25039547	results	We found no significant differences in the age , race , sex , length of wound , number of sutures , or layers of repair in the two groups .	11
25039547	results	The observer 's mean VAS for the Vicryl Rapide group was @ mm ( @ % confidence interval -LSB- CI -RSB- = @ to @ mm ) and for the Prolene group was @ mm ( @ % CI = @ to @ mm ) .	12
25039547	results	The resulting mean difference was @ mm ( @ % CI = -@ to @ mm ; p = @ ) ; thus noninferiority was established .	13
25039547	results	Statistical testing showed no differences in the rates of complications between the two groups , but a higher percentage of the Vicryl Rapide wounds developed complications .	14
25039547	conclusions	The use of absorbable sutures for the repair of simple lacerations on the trunk and extremities should be considered as an alternative to nonabsorbable suture repair .	15
25139873	objective	Aspirin early after intravenous thrombolysis in acute ischemic stroke increases the risk of symptomatic intracranial hemorrhage ( SICH ) , without influencing functional outcome at @ months .	0
25139873	objective	The effect of aspirin on early neurological deterioration ( END ) was explored as a post hoc analysis of the randomized Antiplatelet Therapy in Combination With Recombinant t-PA Thrombolysis in Ischemic Stroke ( ARTIS ) trial .	1
25139873	methods	END , defined as a @ points National Institutes of Health Stroke Scale worsening @ hours after intravenous thrombolysis , was categorized into SICH ( ENDSICH ) and cerebral ischemia ( ENDCI ) .	2
25139873	methods	Multinomial logistic regression was used to assess the effect of aspirin on END .	3
25139873	results	Of the @ patients , @ patients ( @ % ) experienced END ( @ ENDSICH , @ ENDCI ) .	4
25139873	results	Aspirin increased the risk of ENDSICH ( odds ratio , @ ; @ % confidence interval , @-@ @ ) but not of ENDCI ( odds ratio , @ ; @ % confidence interval , @-@ @ ) .	5
25139873	results	After adjustment for other explanatory variables , the association between aspirin and ENDSICH remained significant .	6
25139873	conclusions	In this trial , there is no evidence of an early antithrombotic effect from the addition of aspirin to intravenous thrombolysis in acute ischemic stroke .	7
24917273	objective	To compare the relative effectiveness of methotrexate and mycophenolate mofetil for noninfectious intermediate uveitis , posterior uveitis , or panuveitis .	0
24917273	methods	Multicenter , block-randomized , observer-masked clinical trial .	1
24917273	methods	Eighty patients with noninfectious intermediate , posterior , or panuveitis requiring corticosteroid-sparing therapy at Aravind Eye Hospitals in Madurai and Coimbatore , India .	2
24917273	methods	Patients were randomized to receive @ mg weekly oral methotrexate or @ g twice daily oral mycophenolate mofetil and were monitored monthly for @ months .	3
24917273	methods	Oral prednisone and topical corticosteroids were tapered .	4
24917273	methods	Masked examiners assessed the primary outcome of treatment success , defined by achieving the following at @ and @ months : ( @ ) @ + anterior chamber cells , @ + vitreous cells , @ + vitreous haze and no active retinal/choroidal lesions in both eyes , ( @ ) @ mg of prednisone and @ drops of prednisolone acetate @ % a day , and ( @ ) no declaration of treatment failure because of intolerability or safety .	5
24917273	methods	Additional outcomes included time to sustained corticosteroid-sparing control of inflammation , change in best spectacle-corrected visual acuity , resolution of macular edema , adverse events , subgroup analysis by anatomic location , and medication adherence .	6
24917273	results	Forty-one patients were randomized to methotrexate and @ to mycophenolate mofetil .	7
24917273	results	A total of @ patients ( @ methotrexate , @ mycophenolate mofetil ) contributed to the primary outcome .	8
24917273	results	Sixty-nine percent of patients achieved treatment success with methotrexate and @ % with mycophenolate mofetil ( P = @ ) .	9
24917273	results	Treatment failure from adverse events or tolerability was not different by treatment arm ( P = @ ) .	10
24917273	results	There were no differences between treatment groups in time to corticosteroid-sparing control of inflammation ( P = @ ) , change in best spectacle-corrected visual acuity ( P = @ ) , or resolution of macular edema ( P = @ ) .	11
24917273	conclusions	There was no statistically significant difference in corticosteroid-sparing control of inflammation between patients receiving methotrexate or mycophenolate mofetil .	12
24917273	conclusions	However , there was a @ % difference in treatment success favoring methotrexate .	13
24925006	background	The prevalence of methicillin-resistant Staphylococcus aureus ( MRSA ) respiratory infection in cystic fibrosis ( CF ) has increased dramatically over the last decade , and is now affecting approximately @ % of patients .	0
24925006	background	Epidemiologic evidence suggests that persistent infection with MRSA results in an increased rate of decline in FEV@ and shortened survival .	1
24925006	background	Currently , there are no conclusive studies demonstrating an effective and safe treatment protocol for persistent MRSA respiratory infection in CF.	2
24925006	methods	The primary objective of this study is to evaluate the safety and efficacy of a @-day course of vancomycin for inhalation in combination with oral antibiotics in eliminating MRSA from the respiratory tract of individuals with CF and persistent MRSA infection .	3
24925006	methods	This is a two-center , randomized , double-blind , comparator-controlled , parallel-group study with @:@ assignment to either vancomycin for inhalation ( @mg twice a day ) or taste-matched placebo for @days in individuals with cystic fibrosis .	4
24925006	methods	In addition , both groups will receive oral rifampin , a second oral antibiotic - trimethoprim/sulfamethoxazole ( TMP/SMX ) or doxycycline , protocol determined - mupirocin intranasal cream , and chlorhexidine body washes .	5
24925006	methods	Forty patients with persistent respiratory tract MRSA infection will be enrolled : @ will be randomized to vancomycin for inhalation and @ to a taste-matched placebo .	6
24925006	methods	The primary outcome will be the presence of MRSA in sputum respiratory tract cultures @month after the conclusion of treatment .	7
24925006	methods	Secondary outcomes include the efficacy of the intervention on : FEV@ % predicted , patient reported outcomes , pulmonary exacerbations , and MRSA colony-forming units found in respiratory tract sample culture .	8
24925006	conclusions	Results of this study will provide guidance to clinicians regarding the safety and effectiveness of a targeted eradication strategy for persistent MRSA infection in CF.	9
24559194	background	There is a strong association between weight gain and metabolic events in patients with schizophrenia receiving many of the second-generation antipsychotic agents .	0
24559194	background	We explored the relationship between body mass index ( BMI ) and metabolic events in patients with schizophrenia receiving long-acting injectable paliperidone palmitate ( PP ) in a long-term trial .	1
24559194	methods	We conducted a post hoc analysis of data from a PP study that included a @-week open-label transition ( TR ) and maintenance phase ; a variable duration , randomized , double-blind ( DB ) , placebo-controlled phase and a @-week open-label extension ( OLE ) phase .	2
24559194	methods	Overall , @ patients received PP continuously from study entry through discontinuation or study completion and were grouped by baseline BMI ( kg/m@ ) : underweight ( BMI < @ ; n = @ , @ % ) , normal-weight ( BMI @ - < @ ; n = @ , @ % ) , overweight ( BMI @ - < @ ; n = @ , @ % ) and obese ( BMI @ ; n = @ , @ % ) .	3
24559194	methods	Metabolic treatment-emergent adverse events ( TEAEs ) and changes in related laboratory results from TR baseline were analyzed .	4
24559194	results	PP exposure was similar across BMI groups ; overall mean ( SD ) dose/month was @ ( @ ) mg eq .	5
24559194	results	-LSB- @ ( @ ) mg -RSB- ; median duration of exposure was @ days ( @ to @ days ) .	6
24559194	results	Occurrences of metabolic TEAEs overall by group were @ % ( underweight ) , @ % ( normal-weight ) , @ % ( overweight ) , and @ % ( obese ) .	7
24559194	results	The most common ( @ % ) metabolic TEAE were weight gain and elevated blood levels of glucose , lipids , and insulin .	8
24559194	results	Mean BMI and weight increased in normal-weight and overweight groups at DB endpoint , and in underweight , normal-weight and overweight groups at OLE endpoint ( p @ ) .	9
24559194	results	No consistent trend for increased metabolic-related laboratory values by baseline BMI group was observed .	10
24559194	results	Homeostatic model assessments for insulin resistance indicated preexisting insulin resistance at baseline , with minimal changes at OLE endpoint across baseline BMI groups .	11
24559194	conclusions	Occurrences of metabolic-related TEAEs trended with greater BMI status in patients with schizophrenia treated with PP ; consistent trends in metabolic-related laboratory values were not observed .	12
25203483	background	Fecal immunochemical tests ( FITs ) are recommended to screen average-risk adults for colorectal cancer ( CRC ) .	0
25203483	background	Little research has examined whether a two-sample FIT affects participant uptake , compared with a one-sample FIT .	1
25203483	background	Examining participant uptake is important , as evidence suggests that a two-sample FIT may increase the sensitivity to detect CRC .	2
25203483	objective	This study had two objectives : ( i ) to evaluate FIT completion in a population that received either a one-sample FIT kit ( @-FIT ) or a two-sample FIT kit ( @-FIT ) and ( ii ) to understand whether uptake varies by age , sex , or receipt of prior CRC screening .	3
25203483	methods	We conducted a randomized controlled trial in which @ participants who were aged between @ and @ years and were at an average risk for CRC , and who had requested FITs , randomly received @-FIT ( n = @ ) or @-FIT ( n = @ ) kits .	4
25203483	methods	FIT completion was defined as the completion and return of a one-sample test by the patients in the @-FIT group or of both sample tests by those in the @-FIT group .	5
25203483	methods	Cox proportional hazard regression models were used to determine the independent effect of group type ( @-FIT vs. @-FIT ) on the completion of the FIT , adjusting for age , sex , and receipt of prior CRC screening .	6
25203483	results	The @-FIT group had lower test completion rates ( hazard ratio = @ ; @ % confidence interval = @-@ @ ; P = @ ) after adjusting for age , sex , and receipt of prior CRC screening .	7
25203483	results	Participant uptake did not vary by age , sex , or receipt of prior CRC screening .	8
25203483	conclusions	This unique , rigorous randomized controlled trial found that the @-FIT regimen decreases completion of FIT .	9
25203483	conclusions	Further research is needed to understand whether decreases in participant uptake are offset by increased gains in test sensitivity .	10
25227656	objective	Evaluation of the safety and efficacy of pazopanib , a multikinase angiogenesis inhibitor , in a single-arm , open-label , extension study ( VEG@/NCT@ ) for placebo-treated patients with advanced renal cell carcinoma ( RCC ) from a randomized , double-blind , placebo-controlled phase III study ( VEG@/NCT@ ) .	0
25227656	methods	Patients received pazopanib @ mg/day .	1
25227656	methods	The primary endpoint was the safety and tolerability of pazopanib treatment .	2
25227656	methods	Secondary endpoints included response rate per Response Evaluation Criteria in Solid Tumors , progression-free survival ( PFS ) , and overall survival ( OS ) .	3
25227656	results	Seventy-nine placebo-treated patients from VEG@/NCT@ who experienced disease progression and one pazopanib-treated patient ( an exemption ) were enrolled .	4
25227656	results	Forty-one patients ( @ % ) were treatment-naive ; @ ( @ % ) were cytokine-pretreated .	5
25227656	results	Median exposure to pazopanib was @ months .	6
25227656	results	All patients had discontinued pazopanib at the time of analysis .	7
25227656	results	The most common reason for discontinuation was disease progression ( @ % ) .	8
25227656	results	The most common adverse events were hypertension ( @ % ) , diarrhea ( @ % ) , hair color changes ( @ % ) , anorexia ( @ % ) , and nausea ( @ % ) .	9
25227656	results	The response rate was @ % -LSB- @ % confidence interval ( CI ) : @-@ @ -RSB- ; median PFS was @ months ( @ % CI : @-@ @ ) ; median OS was @ months ( @ % CI : @-@ @ ) .	10

24672940

methods

The treatment period for the two groups was @ weeks .

3

24672940

methods

Patients were followed-up till the @th week .

4

24672940

methods

Clinical symptoms such as fever , lymphadenopathy and hepatosplenomegaly , as well as lab indices such as abnormal lymphocyte percentage , EB virus antibody , virus DNA load , T cell subsets , immunoglobulin , and so on were observed before and after treatment , at week @ and @ of follow-ups .

5

24672940

results

( @ ) The total effective rate at week @ was @ % in the treatment group , higher than that of the control group ( @ % ) , but there was no statistical difference between the two groups .

6

24672940

results

( @ ) The time for defervescence , duration of pharyngeal hyperemia , duration of swollen tonsils was shorter in the treatment group than in the control group ( P < @ ) .

7

24672940

results

The subsidence of lymphadenopathy , hepatomegaly , and abnormal lymphocytes was better in the treatment group than in the control group ( P < @ ) .

8

24672940

results

( @ ) The positive cases of peripheral blood hetero-lymphocyte was significantly reduced after treatment , at week @ and @ of follow-ups both in the treatment group and the control group ( P < @ ) .

9

24672940

results

The expression of IgA and IgM decreased after treatment in the two groups when compared with before treatment in the same group ( P < @ , P < @ ) .

10

24672940

results

IgG in the treatment group also obviously decreased after treatment , at week @ and @ of follow-ups ( P < @ , P < @ ) , while it decreased only after treatment in the control group ( P < @ ) .

11

24672940

results

Activities of AST and ALT in the treatment group and the AST activity in the control group were markedly improved when compared with those before treatment ( P < @ ) .

12

24672940

results

Compared with the control group , the abnormal lymphocyte positive case number obviously decreased in the treatment group after treatment , at week @ and @ of follow-ups ( P < @ ) .

13

24672940

results

( @ ) After treatment , at week @ and @ of follow-ups , CD@ + and CD@ + significantly decreased ; CD@ + , CD@/CD@ , and B cells significantly increased in the two groups , when compared with before treatment ( P < @ ) .

14

24672940

results

NK cells significantly increased more in the treatment group after treatment , at week @ and @ of follow-ups , higher than before treatment as well as the control group ( P < @ ) .

15

24672940

results

( @ ) EB viral DNA and EB viral CA-IgM negative conversion case numbers significantly increased in the two groups after treatment , at week @ and @ of follow-ups ( P < @ ) .

16

24672940

results

Compared with the control group , EB viral DNA and EB viral CA-IgM negative conversion case numbers significantly increased in the treatment group after treatment and at week @ of follow-ups ( P < @ ) .

17

24672940

conclusions

Treatment of EB virus infection by Chinese medical treatment was effective .

18

24672940

conclusions

It could promote the recovery of EB viral infection , and reduce the risk of vicious disease after EB viral infection .

19

25039547

objective

The primary objective was to compare the cosmetic outcomes of traumatic trunk and extremity lacerations repaired using absorbable versus nonabsorbable sutures .

0

25039547

objective

The secondary objective was to compare complication rates between the two groups .

1

25039547

methods

This was a randomized controlled trial comparing wounds repaired with Vicryl Rapide and Prolene sutures .

2

25039547

methods

Pediatric and adult patients with lacerations were enrolled in the study .

3

25039547

methods

At a @-day follow-up , the wounds were evaluated for infection and dehiscence .

4

25039547

methods

After @ months , patients returned to have the wounds photographed .

5

25039547

methods

Two plastic surgeons blinded to the method of closure rated the cosmetic outcome of each wound using a @-mm visual analog scale ( VAS ) .

6

25039547

methods

Using a noninferiority design , a VAS score of @ mm or greater was considered to be a clinically significant difference .

7

25039547

methods

We used a Student 's t-test to compare differences between mean VAS scores and odds ratios ( ORs ) to compare differences in complication rates between the two groups .

8

25039547

results

Of the @ patients enrolled , @ completed the study including @ in the Vicryl Rapide group and @ in the Prolene group .

9

25039547

results

The mean ( SD ) age of patients who completed the study was @ ( @ ) years , and @ were male .

10

25039547

results

We found no significant differences in the age , race , sex , length of wound , number of sutures , or layers of repair in the two groups .

11

25039547

results

The observer 's mean VAS for the Vicryl Rapide group was @ mm ( @ % confidence interval -LSB- CI -RSB- = @ to @ mm ) and for the Prolene group was @ mm ( @ % CI = @ to @ mm ) .

12

25039547

results

The resulting mean difference was @ mm ( @ % CI = -@ to @ mm ; p = @ ) ; thus noninferiority was established .

13

25039547

results

Statistical testing showed no differences in the rates of complications between the two groups , but a higher percentage of the Vicryl Rapide wounds developed complications .

14

25039547

conclusions

The use of absorbable sutures for the repair of simple lacerations on the trunk and extremities should be considered as an alternative to nonabsorbable suture repair .

15

25139873

objective

Aspirin early after intravenous thrombolysis in acute ischemic stroke increases the risk of symptomatic intracranial hemorrhage ( SICH ) , without influencing functional outcome at @ months .

0

25139873

objective

The effect of aspirin on early neurological deterioration ( END ) was explored as a post hoc analysis of the randomized Antiplatelet Therapy in Combination With Recombinant t-PA Thrombolysis in Ischemic Stroke ( ARTIS ) trial .

1

25139873

methods

END , defined as a @ points National Institutes of Health Stroke Scale worsening @ hours after intravenous thrombolysis , was categorized into SICH ( ENDSICH ) and cerebral ischemia ( ENDCI ) .

2

25139873

methods

Multinomial logistic regression was used to assess the effect of aspirin on END .

3

25139873

results

Of the @ patients , @ patients ( @ % ) experienced END ( @ ENDSICH , @ ENDCI ) .

4

25139873

results

Aspirin increased the risk of ENDSICH ( odds ratio , @ ; @ % confidence interval , @-@ @ ) but not of ENDCI ( odds ratio , @ ; @ % confidence interval , @-@ @ ) .

5

25139873

results

After adjustment for other explanatory variables , the association between aspirin and ENDSICH remained significant .

6

25139873

conclusions

In this trial , there is no evidence of an early antithrombotic effect from the addition of aspirin to intravenous thrombolysis in acute ischemic stroke .

7

24917273

objective

To compare the relative effectiveness of methotrexate and mycophenolate mofetil for noninfectious intermediate uveitis , posterior uveitis , or panuveitis .

0

24917273

methods

Multicenter , block-randomized , observer-masked clinical trial .

1

24917273

methods

Eighty patients with noninfectious intermediate , posterior , or panuveitis requiring corticosteroid-sparing therapy at Aravind Eye Hospitals in Madurai and Coimbatore , India .

2

24917273

methods

Patients were randomized to receive @ mg weekly oral methotrexate or @ g twice daily oral mycophenolate mofetil and were monitored monthly for @ months .

3

24917273

methods

Oral prednisone and topical corticosteroids were tapered .

4

24917273

methods

Masked examiners assessed the primary outcome of treatment success , defined by achieving the following at @ and @ months : ( @ ) @ + anterior chamber cells , @ + vitreous cells , @ + vitreous haze and no active retinal/choroidal lesions in both eyes , ( @ ) @ mg of prednisone and @ drops of prednisolone acetate @ % a day , and ( @ ) no declaration of treatment failure because of intolerability or safety .

5

24917273

methods

Additional outcomes included time to sustained corticosteroid-sparing control of inflammation , change in best spectacle-corrected visual acuity , resolution of macular edema , adverse events , subgroup analysis by anatomic location , and medication adherence .

6

24917273

results

Forty-one patients were randomized to methotrexate and @ to mycophenolate mofetil .

7

24917273

results

A total of @ patients ( @ methotrexate , @ mycophenolate mofetil ) contributed to the primary outcome .

8

24917273

results

Sixty-nine percent of patients achieved treatment success with methotrexate and @ % with mycophenolate mofetil ( P = @ ) .

9

24917273

results

Treatment failure from adverse events or tolerability was not different by treatment arm ( P = @ ) .

10

24917273

results

There were no differences between treatment groups in time to corticosteroid-sparing control of inflammation ( P = @ ) , change in best spectacle-corrected visual acuity ( P = @ ) , or resolution of macular edema ( P = @ ) .

11

24917273

conclusions

There was no statistically significant difference in corticosteroid-sparing control of inflammation between patients receiving methotrexate or mycophenolate mofetil .

12

24917273

conclusions

However , there was a @ % difference in treatment success favoring methotrexate .

13

24925006

background

The prevalence of methicillin-resistant Staphylococcus aureus ( MRSA ) respiratory infection in cystic fibrosis ( CF ) has increased dramatically over the last decade , and is now affecting approximately @ % of patients .

0

24925006

background

Epidemiologic evidence suggests that persistent infection with MRSA results in an increased rate of decline in FEV@ and shortened survival .

1

24925006

background

Currently , there are no conclusive studies demonstrating an effective and safe treatment protocol for persistent MRSA respiratory infection in CF.

2

24925006

methods

The primary objective of this study is to evaluate the safety and efficacy of a @-day course of vancomycin for inhalation in combination with oral antibiotics in eliminating MRSA from the respiratory tract of individuals with CF and persistent MRSA infection .

3

24925006

methods

This is a two-center , randomized , double-blind , comparator-controlled , parallel-group study with @:@ assignment to either vancomycin for inhalation ( @mg twice a day ) or taste-matched placebo for @days in individuals with cystic fibrosis .

4

24925006

methods

In addition , both groups will receive oral rifampin , a second oral antibiotic - trimethoprim/sulfamethoxazole ( TMP/SMX ) or doxycycline , protocol determined - mupirocin intranasal cream , and chlorhexidine body washes .

5

24925006

methods

Forty patients with persistent respiratory tract MRSA infection will be enrolled : @ will be randomized to vancomycin for inhalation and @ to a taste-matched placebo .

6

24925006

methods

The primary outcome will be the presence of MRSA in sputum respiratory tract cultures @month after the conclusion of treatment .

7

24925006

methods

Secondary outcomes include the efficacy of the intervention on : FEV@ % predicted , patient reported outcomes , pulmonary exacerbations , and MRSA colony-forming units found in respiratory tract sample culture .

8

24925006

conclusions

Results of this study will provide guidance to clinicians regarding the safety and effectiveness of a targeted eradication strategy for persistent MRSA infection in CF.

9

24559194

background

There is a strong association between weight gain and metabolic events in patients with schizophrenia receiving many of the second-generation antipsychotic agents .

0

24559194

background

We explored the relationship between body mass index ( BMI ) and metabolic events in patients with schizophrenia receiving long-acting injectable paliperidone palmitate ( PP ) in a long-term trial .

1

24559194

methods

We conducted a post hoc analysis of data from a PP study that included a @-week open-label transition ( TR ) and maintenance phase ; a variable duration , randomized , double-blind ( DB ) , placebo-controlled phase and a @-week open-label extension ( OLE ) phase .

2

24559194

methods

Overall , @ patients received PP continuously from study entry through discontinuation or study completion and were grouped by baseline BMI ( kg/m@ ) : underweight ( BMI < @ ; n = @ , @ % ) , normal-weight ( BMI @ - < @ ; n = @ , @ % ) , overweight ( BMI @ - < @ ; n = @ , @ % ) and obese ( BMI @ ; n = @ , @ % ) .

3

24559194

methods

Metabolic treatment-emergent adverse events ( TEAEs ) and changes in related laboratory results from TR baseline were analyzed .

4

24559194

results

PP exposure was similar across BMI groups ; overall mean ( SD ) dose/month was @ ( @ ) mg eq .

5

24559194

results

-LSB- @ ( @ ) mg -RSB- ; median duration of exposure was @ days ( @ to @ days ) .

6

24559194

results

Occurrences of metabolic TEAEs overall by group were @ % ( underweight ) , @ % ( normal-weight ) , @ % ( overweight ) , and @ % ( obese ) .

7

24559194

results

The most common ( @ % ) metabolic TEAE were weight gain and elevated blood levels of glucose , lipids , and insulin .

8

24559194

results

Mean BMI and weight increased in normal-weight and overweight groups at DB endpoint , and in underweight , normal-weight and overweight groups at OLE endpoint ( p @ ) .

9

24559194

results

No consistent trend for increased metabolic-related laboratory values by baseline BMI group was observed .

10

24559194

results

Homeostatic model assessments for insulin resistance indicated preexisting insulin resistance at baseline , with minimal changes at OLE endpoint across baseline BMI groups .

11

24559194

conclusions

Occurrences of metabolic-related TEAEs trended with greater BMI status in patients with schizophrenia treated with PP ; consistent trends in metabolic-related laboratory values were not observed .

12

25203483

background

Fecal immunochemical tests ( FITs ) are recommended to screen average-risk adults for colorectal cancer ( CRC ) .

0

25203483

background

Little research has examined whether a two-sample FIT affects participant uptake , compared with a one-sample FIT .

1

25203483

background

Examining participant uptake is important , as evidence suggests that a two-sample FIT may increase the sensitivity to detect CRC .

2

25203483

objective

This study had two objectives : ( i ) to evaluate FIT completion in a population that received either a one-sample FIT kit ( @-FIT ) or a two-sample FIT kit ( @-FIT ) and ( ii ) to understand whether uptake varies by age , sex , or receipt of prior CRC screening .

3

25203483

methods

We conducted a randomized controlled trial in which @ participants who were aged between @ and @ years and were at an average risk for CRC , and who had requested FITs , randomly received @-FIT ( n = @ ) or @-FIT ( n = @ ) kits .

4

25203483

methods

FIT completion was defined as the completion and return of a one-sample test by the patients in the @-FIT group or of both sample tests by those in the @-FIT group .

5

25203483

methods

Cox proportional hazard regression models were used to determine the independent effect of group type ( @-FIT vs. @-FIT ) on the completion of the FIT , adjusting for age , sex , and receipt of prior CRC screening .

6

25203483

results

The @-FIT group had lower test completion rates ( hazard ratio = @ ; @ % confidence interval = @-@ @ ; P = @ ) after adjusting for age , sex , and receipt of prior CRC screening .

7

25203483

results

Participant uptake did not vary by age , sex , or receipt of prior CRC screening .

8

25203483

conclusions

This unique , rigorous randomized controlled trial found that the @-FIT regimen decreases completion of FIT .

9

25203483

conclusions

Further research is needed to understand whether decreases in participant uptake are offset by increased gains in test sensitivity .

10

25227656

objective

Evaluation of the safety and efficacy of pazopanib , a multikinase angiogenesis inhibitor , in a single-arm , open-label , extension study ( VEG@/NCT@ ) for placebo-treated patients with advanced renal cell carcinoma ( RCC ) from a randomized , double-blind , placebo-controlled phase III study ( VEG@/NCT@ ) .

0

25227656

methods

Patients received pazopanib @ mg/day .

1

25227656

methods

The primary endpoint was the safety and tolerability of pazopanib treatment .

2

25227656

methods

Secondary endpoints included response rate per Response Evaluation Criteria in Solid Tumors , progression-free survival ( PFS ) , and overall survival ( OS ) .

3

25227656

results

Seventy-nine placebo-treated patients from VEG@/NCT@ who experienced disease progression and one pazopanib-treated patient ( an exemption ) were enrolled .

4

25227656

results

Forty-one patients ( @ % ) were treatment-naive ; @ ( @ % ) were cytokine-pretreated .

5

25227656

results

Median exposure to pazopanib was @ months .

6

25227656

results

All patients had discontinued pazopanib at the time of analysis .

7

25227656

results

The most common reason for discontinuation was disease progression ( @ % ) .

8

25227656

results

The most common adverse events were hypertension ( @ % ) , diarrhea ( @ % ) , hair color changes ( @ % ) , anorexia ( @ % ) , and nausea ( @ % ) .

9

25227656

results

The response rate was @ % -LSB- @ % confidence interval ( CI ) : @-@ @ -RSB- ; median PFS was @ months ( @ % CI : @-@ @ ) ; median OS was @ months ( @ % CI : @-@ @ ) .

10